The oral drug, nilotinib, is used to treat chronic myeloid leukemia, and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines and Tunisia.
Where OEMs in the past could concentrate on securing supply of expensive components, now they have to think about everything that goes into production, including raw materials, too.